

Supplementary information

Endocytosis deficient murine Xcl1-fusion vaccine enhances protective antibody responses in mice.

Arnar Gudjonsson¹, Tor Kristian Andersen¹, Vibeke Sundvold-Gjerstad³,
Bjarne Bogen^{1,2,*}, and Even Fossum^{1,*}

¹K.G. Jebsen Centre for Influenza Vaccine Research, Institute of Immunology,
University of Oslo and Oslo University Hospital, 0450 Oslo, Norway.

²Centre for Immune Regulation, Institute of Immunology, University of Oslo
and Oslo University Hospital, 0027 Oslo, Norway.

³Department of Molecular Medicine, Institute of Basic Medical Sciences,
University of Oslo, 0317 Oslo, Norway.

* Correspondence and requests for materials should be sent to:

Even Fossum or Bjarne Bogen

Institute of Immunology

Oslo University Hospital

Songsvannveien 20

0027 Oslo,

Norway

Phone: +47 23 07 30 45

Fax: +47 23 07 35 10

Even.fossum@rr-research.no

Bjarne.Bogen@medisin.uio.no

SUPPLEMENTARY FIGURE.

(A) Schematic representation of the vaccibody molecule containing a targeting unit (Xcl1 or Xcl1(Δ 1)), a dimerization domain and antigenic unit (hemagglutinin or mCherry). (B) BM-derived Flt3L-induced DCs were defined as CD45R/B220⁻CD11c⁺ and further divided into CD24⁺ (cDC1) or CD11b⁺ (cDC2). (C) Splenic DCs were defined as CD3e⁻CD19⁻CD49b⁻Ly6G⁻MHC-II⁺CD11C⁺ and further split into CD24⁺ (cDC1) or CD11b⁺ (cDC2). (D) Spleens were harvested from mice three days after i.p. injection with 200 μ g of depleting or isotype matched antibodies. T cells were defined as CD45R/B220⁻CD3⁺.

Supplementary Figure

